From Traditional Agents to NOACs: A Deep Dive into the Factors Propelling Apixaban Market Success and Therapeutic Preference
The evolution of anticoagulation therapy, moving away from traditional, challenging vitamin K antagonists toward Novel Oral Anticoagulants (NOACs), is a story of therapeutic progress driven by superior patient-centric attributes. Apixaban has played a starring role in this narrative, successfully capturing significant market share due to a compelling combination of clinical efficacy, ease of...
0 Комментарии
0 Поделились